Novo Nordisk and Eli Lilly have both reported their Q3 results. Below are some of the headlines related to their diabetes business. Novo Nordisk OG2023SC, an oral GLP-1 analogue, has been discontinued based on encouraging results for an enhanced oral semaglutide formulation. US FDA decision on cardiovascular indication for Rybelsus® is expected in the first …
Category Archives: Pharmaceuticals
Roche reports very strong sales growth in the first nine months of 2019 – outlook raised
Roche issued a press release on its nine month sales with the following headlines. Group sales increase 10% at constant exchange rates and 9% in Swiss francs, due to new products Pharmaceuticals Division sales up 12%, driven by high demand for recently launched medicines, mainly Ocrevus, Hemlibra, Tecentriq and Perjeta Diagnostics Division sales grow 4%, primarily …
J&J tops estimates
Johnson & Johnson [$JNJ] issued a press release before the market opened on its third quarter results with the following headlines: Sales of $20.7 billion reflecting growth of 1.9%, operational growth of 3.2%* and adjusted operational growth of 5.2%* EPS of $1.81 increased 25.7%; adjusted EPS of $2.12 increased 3.4%* Company increasing Full Year Sales …